175 related articles for article (PubMed ID: 21893500)
1. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
Skates SJ; Mai P; Horick NK; Piedmonte M; Drescher CW; Isaacs C; Armstrong DK; Buys SS; Rodriguez GC; Horowitz IR; Berchuck A; Daly MB; Domchek S; Cohn DE; Van Le L; Schorge JO; Newland W; Davidson SA; Barnes M; Brewster W; Azodi M; Nerenstone S; Kauff ND; Fabian CJ; Sluss PM; Nayfield SG; Kasten CH; Finkelstein DM; Greene MH; Lu K
Cancer Prev Res (Phila); 2011 Sep; 4(9):1401-8. PubMed ID: 21893500
[TBL] [Abstract][Full Text] [Related]
2. Personalizing CA125 levels for ovarian cancer screening.
Dorigo O; Berek JS
Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498
[TBL] [Abstract][Full Text] [Related]
3. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
[TBL] [Abstract][Full Text] [Related]
4. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
5. CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study.
Gebhart P; Singer CF; Gschwantler-Kaulich D
BMC Cancer; 2023 Jul; 23(1):610. PubMed ID: 37393265
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.
Hu X; Zhang J; Cao Y
BMC Cancer; 2022 May; 22(1):544. PubMed ID: 35568827
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
9. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
[TBL] [Abstract][Full Text] [Related]
10. Predicting Circulating CA125 Levels among Healthy Premenopausal Women.
Sasamoto N; Babic A; Rosner BA; Fortner RT; Vitonis AF; Yamamoto H; Fichorova RN; Tjønneland A; Hansen L; Overvad K; Kvaskoff M; Fournier A; Romana Mancini F; Boeing H; Trichopoulou A; Peppa E; Karakatsani A; Palli D; Pala V; Mattiello A; Tumino R; Grasso CC; Onland-Moret NC; Weiderpass E; Quirós JR; Lujan-Barroso L; Rodríguez-Barranco M; Colorado-Yohar S; Barricarte A; Dorronsoro M; Idahl A; Lundin E; Sartor H; Khaw KT; Key TJ; Muller D; Riboli E; Gunter MJ; Dossus L; Kaaks R; Cramer DW; Tworoger SS; Terry KL
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1076-1085. PubMed ID: 30948451
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
[TBL] [Abstract][Full Text] [Related]
12. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
13. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
[TBL] [Abstract][Full Text] [Related]
15. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
16. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ
Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052
[TBL] [Abstract][Full Text] [Related]
17. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
[TBL] [Abstract][Full Text] [Related]
18. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.
Ikeda Y; Hasegawa K; Kurosaki A; Miyara A; Hanaoka T; Shintani D; Imai Y; Nishikawa T; Oda K; Fujiwara K
Oncol Res Treat; 2015; 38(6):276-81. PubMed ID: 26045023
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
20. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
